 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma |
 |
 |
 |
 |
Phase: |
 |
Phase 1/2 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1347 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
60: Requires occasional assistance but is able to care for most of own needs |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Sometimes Allowed Histologically confirmed oligodendroglioma or mixed oligoastrocytoma
Grade 2-4
Recurrent disease
Failed prior surgery, radiotherapy, nitrosourea-based therapy, or temozolomide chemotherapy regimen
Progressive disease by MRI or CT scan
No more than 2 prior chemotherapy regimens
No prior or concurrent significant intratumoral hemorrhage |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
11/27/2005 |
 |
 |
 |
 |
Tumor Types: |
 |
Mixed Glioma Oligodendroglioma High Grade Oligodendroglioma Low Grade |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
No prior interstitial chemotherapy, including carmustine wafers, unless separate lesion seen on MRI outside of prior treatment field |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy |
 |
 |
 |
 |
Contact: |
 |
Alan R. Berg MD Bryan LGH Medical Center West
Lincoln, NE 68502 USA Phone: 402-420-7000 Fax: E-mail: Website: |
 |
 |